Steven F. Weiner, MD Introduces Facial Ultrasound to Improve Safety with Cosmetic Facial Filler Treatments

Superior Orbital Artery at The Superior Orbital Notch

Dr. Steven F. Weiner with Dr. Leonie Schelke and Dr. Oscar Janssen at Instructor Training

Ultrasound of Temple Area Showing Superficial Temporal Artery, Temporalis and Intermediate Temporal Fat Pad

Using ultrasound, Dr. Weiner is able to visualize facial vasculature, previous filler placement, and can evaluate complications from prior filler injections.

Using ultrasound in facial aesthetics will soon become the gold standard for safe filler injections. Ultrasound is particularly valuable in treating filler complications.”

— Steven F. Weiner, MD

SANTA ROSA BEACH, FLORIDA, UNITED STATES, March 28, 2020 / — Dr. Steven F. Weiner, a Facial Plastic Surgeon in Santa Rosa Beach, Florida, becomes one of the first physicians to bring facial ultrasound into a cosmetic practice in the United States. While ultrasound has been used by most of the medical specialties to assist in anatomical visualization and assisted injections, the U.S. facial aesthetics industry has not adopted it's use…until now. The practice of using ultrasound for facial anatomy and fillers was introduced in 2010 by a group of physicians in Amsterdam, Dr. Leonie Schelke (Cosmetic Physician), Dr. Oscar Janssen (Radiologist), Dr. Peter Velthuis (Dermatologist), and Dr. Constantijn Pleiter (Radiologist). This group of physicians created the training program, the worldwide leader in ultrasound training for facial aesthetics. In 2019, Dr. Weiner attended their instructor course in Amsterdam.

"Using ultrasound in facial aesthetics will become the gold standard for safe filler injections" says Dr. Weiner. "While many providers are very proficient in facial anatomy, there are anatomic variations, particularly vascular anatomy, which can only be determined using ultrasound during a patient's office evaluation and treatment." One of the rare complications of filler injections is a vascular occlusion, an obstruction of an artery caused by injection of filler within the vessel. Ultrasound use in the physician's office is a painless, noninvasive procedure that can be used to evaluate the critical vascular structures such as the facial artery, superficial temporal artery, infraorbital artery, superior and inferior labial artery, supratrochlear and supraorbital arteries, angular artery and dorsal nasal artery. "Routine use of ultrasound for every filler injection is not necessary, but if there is any question by the provider of the vascularity in critical areas, ultrasound can be helpful."

In the rare case of vascular occlusion, ultrasound is able to determine the area of blockage and to visualize the "pocket of filler". If the offending filler injected is a hyaluronic acid (HA) filler, there is a reversal agent called hyaluronidase, which can be injected to dissolve the filler. "While hyaluronidase can be injected in the general vicinity of occlusion, using ultrasound guidance allows for more specific and directed injections and most likely, better outcomes" states Dr. Weiner. Another complications of fillers, such as delayed swelling, nodules, or granulomas, can also be visualized using facial ultrasound. These complications often will require therapeutic injections which can be guided using ultrasound.

Facial ultrasound can be used as an educational tool for both providers and patients, to highlight anatomy, and to visualize previously placed filler. Often patients are interested in seeing whether past filler is still present. Conversely, Dr. Weiner has had many cases of filler still present up to 10 years after injection, particularly around the eyes, of HA filler that typically lasts 1 year.

The future of facial ultrasound adoption in the U.S. will grow exponentially over the next couple years. Dr. Weiner is already planning training courses at conferences including the Los Angeles Multi-Specialty Cosmetic Association (LAMCA) and Aesthetic Next 2. Future trainings will be announced in the near future and private trainings can be arranged as well by calling his office: 850.622.1214.

Dr. Weiner positions his practice, The Aesthetic Clinique, as one of the most technologically advanced cosmetic centers in the United States. Dr. Weiner lectures and trains worldwide on advanced injection techniques and aesthetic technologies. The Aesthetic Clinique was awarded the Best Aesthetic Practice in the U.S. in 2018 at The Aesthetic Show. In 2019 and 2020, The Aesthetic Clinique was voted Best Medspa and Best Doctor from The Best in Destin awards. He is one of the world's authorities on Radiofrequency Microneedling and recently published the most comprehensive review of the technology and studies in the Facial Plastic Surgery Clinics of North America. He was recently highlighted on "The Doctors Show" for his trademarked "reJAWvenation" technique for jawline rejuvenation using dermal fillers. Dr. Weiner has over 26 years of experience in the aesthetic industry.

Steven F Weiner
The Aesthetic Clinique
+1 850-622-1214
email us here
Visit us on social media:

Source: EIN Presswire

Vitro Biopharma First Quarter ended January 31st 2020 Financial Results of Operations

Vitro Biopharma is pleased to announce a record 1st comparative quarter in Total Revenues of $225,921 vs $192,895 an increase of 17% versus last year.

Vitro Diagnostics Inc. (OTCMKTS:VODG)

Vitro is pleased to have recently been recognized by Bioinformant as "a Company Tracking the Coronavirus".”

— Dr. James Musick

GOLDEN, CO, USA, March 28, 2020 / — Vitro Biopharma First Quarter ended January 31st 2020 Financial Results of Operations

Golden, Colorado-March 26, 2020-Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st, 2020 financial results of operations.

Vitro Diagnostics Inc. (“Vitro Biopharma”) is pleased to announce a record 1st comparative quarter in Total Revenues. Vitro Biopharma recorded 1st quarter revenues of $225,921 vs $192,895 an increase of 17% over the same comparative quarter last year. In addition, Stem Cell treatments accounted for 74% of the revenues up from 71% of the revenues in the prior comparative quarter last year. Current quarter stem cell revenues were $167,750 for the 1st quarter ended January 31, 2020 vs $137,123 for the first quarter ended January 31, 2019.

The company’s gross profit margins improved to 75% up from 73% in the comparative prior year’s quarter. Gross margin improvement is in line with the strategic direction of the company to expand the market of its flagship product AlloRx™ Stem Cells. The company’s clean-room lab expansion last year and expanded Stem Cell manufacturing using its patent-pending cell line, has increased efficiencies and lowered production costs.

Overall operating expenses increased in the quarter to $193,385 from $147,398 in the prior year’s comparative quarter. The increase in expenses reflects additional investment as the Company expands its capability to service its strategic direction of offshore Stem Cell treatments while also expanding into US markets. The company expended additional resources on external consultants supporting our regulatory status in maintaining ISO9001 & ISO13485 certifications, expanding our efforts to approach US markets through FDA filings and advancement of existing patent filings.

The company’s first quarter is its most seasonal quarter as the period between Thanksgiving and the New Year is slow for all the company’s revenue lines of Nutra Vivo™/STEMulize, AlloRx™ Stem Cells, private labeled InfiniVive MD™ Stem Cell Serum and our core research products.

During the quarter the company achieved and pursed the following company objectives

• Series A Convertible Preferred Stock Offering:

During the quarter the company commenced a Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company sold $450,000 of the Series A Convertible Preferred Stock during the quarter. The company has additional interest in the offering and subsequent to the quarter has sold an additional $50,000 unit for a total to date of $500,000. The company has additional interested parties for approximately $200,000. The offering is for a total of $1,000,000.

• Expansion of revenues & results from the clinical trials in the Cayman Islands:

Our partnership with DVCStem in the Cayman Islands continued to advance through treatment of new & previous patients. This IRB-approved protocol targets patients with inflammatory conditions including multiple sclerosis, systemic inflammation and new indications including Crohn's disease, Alzheimer’s disease and COPD. To date we have treated 60 patients including repeat treatments. There have been no serious adverse events and we continue to gain evidence of efficacy. One of the initial MS patients has now received a second transplant of our AlloRx™ Stem Cells and he has reported significant therapeutic benefits of both the initial and subsequent therapy. He had received an earlier transplant of adipose-derived MSCs that was effective, but the improvement lasted 3 months while AlloRx™ Stem Cell therapy lasted 18 months. We had predicted such a clinical outcome based on significantly higher potency of umbilical cord MSCS compared to those derived from adipose tissue or bone marrow. The Crohn’s disease patient showed significant improvement as did both the AD & COPD patients.

• Further Expansion into US Markets-FDA IND:

The strategic development of our stem cell therapies involves pursuit of both offshore and domestic markets. The partnership with DVC Stem, our IRB-approved trial in the Bahamas together with other strategic opportunities represent offshore operations & prospects. During Q1 2020, we initiated expansion into US therapeutic markets through development of an Investigational New Drug (IND) application for submission to FDA. Once approved, an IND allows the conduct of clinical trials for specific medical conditions in the US.

Given the current COVID-19 pandemic, our initial IND application is for use of AlloRx™ Stem Cells in treatment of Coronavirus infections. This is supported by clinical studies showing that 17 critically ill patients responded favorably to IV infusion of umbilical cord-derived MSCs. All patients were receiving assisted ventilation but 3 days following stem cell therapy, were removed from ventilators and subsequently discharged from the hospital. We are pursuing discussions with FDA to establish the appropriate regulatory pathway and expedited review options given the current emergency circumstances. (See Subsequent Events, below, for additional discussion of our COVID-19 response.) Once our initial IND is in place, we have plans for additional INDs for stem cell therapy of musculoskeletal conditions and Alzheimer’s disease.

• PR Medica Opportunity:

We have received an initial order of AlloRx™ Stem Cells for testing purposes by PR Medica located in Cabo San Lucas. Given successful test results, we anticipate subsequent new revenue generation from this customer.

• InfiniVive MD™ Stem Cell Serum:

Vitro Biopharma’s cosmetic topical stem cell serum is being distributed by InfiniVive MD™ into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company’s product is being offered in 10 cosmetic clinics.

Our partner, Dr Jack Zamora, MD was a keynote speaker at a master session at the American Academy of Cosmetic Surgery annual meeting in late February. The topic of his presentation was “Topical Stem Cells, Exosomes and Conditioned Media Serums in Aesthetics.” This was the official launch of the InfiniVive-MD platform including: Dailey Serum, Stem Cell Serum 2.0 & Exosomes within the product line. Vitro Biopharma will manufacture & private label these new products for distribution in the US. We anticipate InfiniVive MD growth, development and revenues to mirror the development of Apyx subdermal plasma skin tightening as a cosmetic treatment and technique that has gone global.

• Research and Development, Facility Expansion & Patent Prosecution

Our core research product sales continued to expand in Q1 2020. Our facility expansion continued with addition of manufacturing capacity and development of plans to add operational facility to increase outputs further by 100% or more. We were also in discussions with the USPTO regarding our pending patents for our novel stem cell therapy and stem cell activation technology. We continue to work closely with our examiner and have established communication channels to facilitate awards of these patents.

• SUBSEQUENT EVENTS: COVID-19 Opportunity and Risks

The COVD-19 pandemic is a significant obstacle for all business. However, Vitro Biopharma is uniquely positioned since we have a potential effective therapy. This is based on 3 independent reports showing efficacy of stem cell therapy in 17 COVID-19 patients. All were treated with IV umbilical cord MSCs comparable to AlloRx™ Stem Cells and all 17 required respiratory assistance but within 3-4 days of treatment, were able to breath without ventilators and were discharged within 14 days. On the contrary, untreated patients on ventilators have death rates of 50% or more. We have received a formal request to supply AlloRx™ Stem Cells for compassionate use from a major university medical center and several other potential clinical partners have also expressed interest in using our cells to treat COVID-19 patients. We are presently working with the FDA to gain authority to begin clinical testing in the US. We are currently assessing the overall financial impact of the COVID-19 pandemic on our business, but this depends on overall control of the pandemic. There have been no staff layoffs and our workers are considered essential since we conduct essential research to the COVID-19 response.

Dr. Jim Musick, CEO of Vitro Biopharma, said, “We are very pleased with the increased revenue growth during our first quarter 2020 compared to the prior year However all our resources are currently focused on the emergency response to the COVID-19 pandemic and increasing our inventory of AlloRx to satisfy anticipated emergency demand to treat critically ill COVID-19 patients.” The Company is working to get expedited clinical trial approvals to sell our AlloRx Stem Cells to hospitals coping with the pandemic. Vitro is pleased to have recently been recognized by Bioinformant as "a Company Tracking the Coronavirus". We anticipate clinical progress in the effectiveness of our stem cell therapies while expecting to see a reduction in our offshore and cosmetic revenues for the next quarter or two. The company is in a good cash position to weather this storm and simultaneously advance its AlloRx stem cell therapies into clinical trials.

In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10+years’ experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We are leveraging our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.

Sincerely yours,

James R. Musick, PhD.
President, CEO & Chairman of the Board

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Dr. James Musick
Chief Executive Officer
Vitro BioPharma
(303) 999-2130 Ext. 3

Source: Vitro Diagnostics, Inc.

John Evans
Vitro BioPharma
+1 303-601-7855
email us here

Source: EIN Presswire

As Coronavirus Grows, Gun Sales Rise – An Alternative Self Defense Option for Everyone Does Exist

Reflex Protect®, offers a self-defense spray that empowers people to be their own first responder

Be Your Own First Responder

Citizens worry about violence, but not everyone wants to own a gun. Reflex Protect®, is a self-defense spray allowing people to be their own first responder.

A non-lethal solution that addresses violence, but in a non-violent way.”

— Our goal is to bring peace of mind to the public

MISSOULA, MONTANA, UNITED STATES , March 28, 2020 / — Sales of guns and ammunition are way up due to fears about Coronavirus. reported transactions are up 68%. People are living in fear of violence and looking for solutions, but not everyone feels comfortable owning a gun. Reflex Protect® offers a proven non-lethal, non-violent alternative.

“Our Presidia Gel® is delivered through a patented technology spray head, that easily and accurately shoots the perpetrator up to 20 feet away and delivers a rapid onset of temporary blindness and pain, debilitating the attacker until help arrives,” says Joe Anderson, Co-Founder and President. “If you can use a spray cleaner you can use Reflex Protect,” he says.

About Joe Anderson. In 1993 on a Thursday, just before 3pm, a gunman entered Joe Anderson’s former workplace in San Francisco and killed 9 of his friends and colleagues. For years all he could think about was “how can we stop this from ever happening again?” “When my friend Steve Mangold came to me with this product, I thought, “I wish this had been in the receptionist’s hands 25 years earlier; it might have changed everything.”

Mangold and Anderson started Reflex Protect and developed a non-lethal solution that addresses violence, but in a non-violent way. “Our goal now is that every receptionist, front line worker, ER triage nurse and teacher can feel empowered and protected – without having to face the use of violent force,” says Anderson.

Joe is available for interviews and to discuss:
• Specific safety tips for home, work and public spaces
• The “gun vs. no gun” safety debate in light of Coronavirus

Karen Leland
Reflex Protect
+1 415-260-4615
email us here
Visit us on social media:

Source: EIN Presswire

China Cosmetics Market Outlook 2025- by Goldstein Research

The low-to-mid priced products are majorly offered by the local players in China, whereas the foreign players have focus on the high end segment.

NEW YORK, NY, UNITED STATES OF AMERICA, March 28, 2020 / — China Cosmetics Market Outlook 2025

According to the Goldstein Research report , In terms of competition among the players in cosmetic industry, the low-to-mid priced products are majorly offered by the local players in China, whereas the foreign players have focus on the high end segment.

China cosmetics industry is the fastest growing market in the world over the past few years. the consumer’s attitude towards cosmetics market has drastically changed in China. In present scenario consumers in China tends to get less influenced by the media advertisement & prefer to gather information of a product through various sources.

Report is available at:-

Covered in this China Cosmetics Market Report are
“China Cosmetics Market Outlook 2025” by Goldstein Research contains detailed overview of the China Cosmetics Market in terms of market segmentation by analysis basis, therapy type and geography. The Report highlights the competitive outlook of major global players that includes the business strategies, product portfolio, revenue distribution, financial analysis, R&D activities, and investments. The in-depth analysis of China Cosmetics Market report will help the clients to assess their business strategies as per the competitive environment in the market space.

Major players covered in this China Cosmetics Market report are :

the Estée Lauder Companies Inc.
Ralph Lauren Corporation
Avon Products Inc.
The Procter & Gamble Company
Unilever PLC
Bee & Flower

Request for Sample Report at:-

Further, China Cosmetics Market Report encompasses the major trends & opportunities, market dynamics and other growth factors of the market. The China Cosmetics Market outlook also comprises of key challenges, risk analysis, BPS analysis, SWOT Analysis and Market Attractiveness. The report also highlights the expert analysis to provide a complete overview of the market including the PESTLE analysis of each region and country.
About Goldstein Research
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear-cut forecasts. Our market research reports provide in-depth analysis of global and regional variations along with competitors’ overview.
Our analysts working on chemicals construction to help various tech-giants, tech start-ups and entry players to assess the current and upcoming business scenario. We believe in the vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.

Contact for more Info:
Steve Blade
(Global Sales Head)
USA: + 1-646-568-7747
Canada: 1-437-886-1181
UK: +44-203-318-6627

Steve blade
Goldstein Research
+1 6465687747
email us here

Steve Blades
Goldstein Research
+1 646-568-7747
email us here
Visit us on social media:

Source: EIN Presswire

African Businesses to Benefit from Partnership Agreement Signed by Menes Konsult and Asian Franchise Academy

Africa Franchise Academy

Asian Franchise Academy sets eyes on global expansion

BANGKOK, THAILAND, March 28, 2020 / — African Businesses to Benefit from Partnership Agreement Signed by Menes Konsult and
Asian Franchise Academy

About Menes Konsult
About EuropLaw


The doors were thrown wide open for African businesses to benefit from franchising opportunities and also take their brands beyond their borders when the Nigerian-American legal and business firm, Menes Konsult, signed a formal partnership agreement with Asian Franchise Academy (AFA) on March 17, 2020. This partnership also positions Asian Franchise Academy to become a leader in business and franchising consultancy in Africa. It also allows AFA’s clients all over the world to benefit from the legal and business services offered by the team of lawyers and business specialists at Menes Konsult. Africa Franchise Academy, the new company formed by the partnership, will trade as Africa Franchise Alliance and will be incorporated in Singapore and Menes Konsult will own majority shares in the new company.

The parties have been discussing and negotiating for a number of months before eventually reaching a consensus on all terms of the partnership. The agreement was signed on behalf of Menes Konsult by its president, Attorney N. Jude Menes of Dallas, Texas, while Mr. Patrick Mauser, the Founder and CEO of Asian Franchise Academy signed on behalf of AFA.

Commenting on the agreement, Attorney Menes remarked that, through the Africa Franchise Academy, African entrepreneurs who have invested lots of resources and built a great brand will now have the opportunity to take their brands not only Africa-wide, but also worldwide. He observed that, although the idea of franchising is still new to Africa, many homegrown African brands can do very beyond their borders just like McDonalds, Dominos Pizza, Burger King, have done outside America. He stated that he is confident that his firm’s partnership with the Asian Franchise Academy (AFA) will accomplish the intended goal of making African brands popular outside the continent because AFA and Menes Konsult not only have the right vision, experience, commitment, but the timing is also very right.

On his part, Mr. Mauser expressed delight at the formation of the partnership and remarked that Menes Konsult is well-positioned to best serve existing and potential clients of AFA in Africa. He stated that the newly formed partnership is a strategic development which will allow AFA to substantially grow in Africa. According to Mr. Mauser, AFA is now poised to become a great force within the SME sector in Africa. He stated that his vision is to bring together the Asian, African, and Arabian markets into one outstanding global force that will provide great franchising and expansion opportunities to African businesses and brands.

Menes Konsult was formed through collaborative efforts of African professionals in the United States who are committed to promoting the development of African countries by facilitating business relations between Africa and the rest of the world. The firm represents foreign companies and investors to successfully do business in Africa by helping them avoid the risks created by fraud, corruption, and other local issues in the continent. Additionally, the firm assists African governments and companies to access funds to execute projects that are not only potentially profitable, but also have the potential to improve the lives of citizens. Menes Konsult has offices and/or accredited representatives in major African cities.

Press Release -End-

Patrick Mauser
Asian Franchise Academy
+66 835685612
email us here
Visit us on social media:

Europ Law – Menes Konsult

Source: EIN Presswire

Wired &Wireless Microphones Market Global Overview & 2020 Opportunities Report adds Microphones Global Market Report 2020 from its research database.

The global microphones market was worth $2.48 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 0.43% and reach $2.53 billion by 2023.

— Abdul Wasay

LONDON, GREATER LONDON, UK, March 27, 2020 / — The global microphones market is expected to grow at a rate of about 0.43% and reach $2.53 billion by 2023. The widespread adoption of smartphones is globally contributing to the growth of the microphones market. The demand for mobiles is directly proportional to demand for microphones. However, obstructions and the signal blockages are some of the technical difficulties that limit the growth of the microphones market.

The microphones market consists of sales of microphones and related services that are used in various applications such as in hearing aids, radios, large venues & events, educational institutions, government and military, and hospitality. A microphone is a type of transducer that converts acoustical energy from one form to another.

Request For A Sample For The Global Microphones Market Report:

The global microphones market is further segmented based on type and geography.
By Type – The microphones market is segmented into wired microphones and wireless microphones.
By Geography – The global microphones is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, the North American microphones market accounts for the largest share in the global microphones market.

Trends In The Microphones Market
In both developing and developed economies, devices such as Amazon Alexa and Google Home are gaining popularity. These devices are manufactured by extensive use of microphones, which can respond to human voices. A smart assistant can perform various tasks such as playing music, news, etc. with the help of software that is installed in these smart devices. This is a major trend in the microphones market.

Potential Opportunities In The Microphones Market (
With improved earning capacity and advances in technology, the scope and potential for the global microphones market is expected to significantly rise in the forecast period.

Major players in the market are Knowles Corporation, Goertek, STMicroelectronics, BSE, NeoMEMS Technologies, Hosiden, InvenSense, Cirrus Logic, AAC Technologies, and Infineon Technologies.

Microphones Global Market Report 2020 is one of a series of new reports from The Business Research Company that provides microphones market overviews, analyzes and forecasts microphones market size and growth for the global microphones market, microphones market share, microphones market players, microphones market size, microphones market segments and geographies, microphones market trends, microphones market drivers and microphones market restraints, microphones market’s leading competitors’ revenues, profiles and market shares. The microphones market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Where To Learn More
Read Microphones Global Market Report 2020 from The Business Research Company for information on the following:
Markets Covered: global microphones market
Data Segmentations: microphones market size, global and by country; historic and forecast size, and growth rates for the world, 7 regions and 12 countries
Microphones Market Organizations Covered: Knowles Corporation, Goertek, STMicroelectronics, BSE, NeoMEMS Technologies, Hosiden, InvenSense, Cirrus Logic, AAC Technologies, and Infineon Technologies
Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
Time Series: Five years historic (2015-19) and forecast (2019-23).

Place a Direct Purchase Order Of Complete Report (Individual License USD 4000)@

Other Information And Analyses: PESTEL analysis, microphones market customer information, microphones market product/service analysis – product examples, microphones market trends and opportunities, drivers and restraints, key mergers and acquisitions, key metrics covered: number of enterprises, number of employees, global microphones market in 2020 – countries offering most new opportunities

Sourcing and Referencing: Data and analysis throughout the report are sourced using end notes.
Strategies For Participants In The Microphones Industry: The report explains a number of strategies for companies in the microphones market, based on industry trends and company analysis.

Opportunities For Companies In The Microphones Sector: The report reveals where the global microphones industry will put on most $ sales up to 2023.

Interested to know more about The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. Here is a list of reports from The Business Research Company similar to Microphones Global Market Report 2020:

Audio Equipment Global Market Report 2020

Wireless Speakers Global Market Report 2020

Voice Prosthesis Devices And Equipment Global Market Report 2020

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:

Source: EIN Presswire

Garrett Hofer Discusses the Health Benefits of Rugby for Children

Garrett Hofer CT

EAST LYME, CT, UNITED STATES, March 27, 2020 / — The game of rugby is a fast-moving sport that involves considerable speed and coordination. Because it’s a ball sport, it’s good for adults, college-level students, and kids of all ages who want to play competitively or even just for fun. As a hybrid of what most people know about soccer and football, rugby is a great pastime for thousands of people all over the world. These players are getting more than just physical conditioning says Garrett Hofer CT, coach and co-founder of the Shoreline Spartans Rugby program. Here, Garrett Hoffer talks about some of the health benefits he has seen in children who play rugby.

Cardiovascular Fitness, Strength, and Coordination
One of the biggest benefits Garrett Hofer CT has seen in kids that take up the sport is that they get in shape relatively quickly. “It’s easy to get exercise when you’re running during the whole game,” Garrett Hofer says. Unlike the American game of football where breaks and time-outs are called periodically, there are almost no time-outs in rugby, he adds. “It’s continuous, and you can really work up a sweat playing it,” he explains. Like football, the game requires strength, speed, and coordination. Garrett Hofer CT says it’s one of the best sports for your heart, lungs, and other major muscle groups such as the legs. Rugby offers a unique combination of speed and cardiovascular conditioning in a Team Environment.

Team Building and Social Benefits
Unlike some sports that rely mostly on individual team members, rugby depends on the team working as a unit. The members work together in unison towards a singular goal. Garrett Hofer CT says each player must learn to work together with team members which makes each player equally important on the team. This promotes individual contributions to the overall good of the Team. Garrett Hofer explains: “I’ve found it to be a great tool for teaching teamwork and good sportsmanship to players of all ages.”

Self-Esteem and Confidence
Because the game requires the player to get in shape quickly and learn to work together as a team, Garrett Hofer CT has seen some remarkable changes over time for the children who play. “As coaches, we find it very rewarding to help children excel in a sport and also build their confidence. We frequently encounter children that may initially have low self esteem or struggle in other sports but they excel in the supportive team environment that we’ve created.” This increased confidence can carry over into the child’s schoolwork and home life as well. In conclusion, Garrett Hofer states: “We enjoy helping children improve their fitness, self esteem, confidence, and ability to work with others, all while having fun!

Caroline Hunter
Web Presence, LLC
+1 7862338220
email us here

Source: EIN Presswire

Science Smart Toys kickstarter campaign underway

Science Smart Toys logo

Top of box which is the toy.

Come help us teach kids to learn,explore,and discover our world.

Learn,Explore, Discover”

— Jennifer Reyes

KANSAS CITY, MISSOURI, UNITED STATES, March 27, 2020 / — Now Seeking Community Support via Kickstarter, This Scientific & Educational Toy Store is Founded by an American Inventor & Mother of Nine Children!
Jennifer Reyes is a Kansas City based American inventor and a devoted mother of nine children. She has recently launched a crowdfunding campaign on Kickstarter for Science Smart Toys, an upcoming toy outlet based on scientific and educational toys that will help children discover, learn and explore in a fun way. The project took 16 years in the making and this campaign will give Jennifer a chance to make her lifelong dream come true.

“The project has been patent pending for nearly two years and will be awarded a patent soon,” said Jennifer Reyes, the Founder of Science Smart Toys, while introducing this project to the Kickstarter community. “I am now raising money to start the process of manufacturing these toys and I need your help to bring this project to life,” she added. According to Jennifer, Science Smart Toys will create a passion for learning in children by blending education and fun together.

The Kickstarter Campaign is located on the web at:

All funds raised through this Kickstarter campaign will play a major role in the manufacturing of these smart toys. Moreover, the goal of this Kickstarter campaign is to raise a sum of US$ 300,000 and Jennifer is offering rewards for the backers with worldwide shipping. Furthermore, more details are available on the Kickstarter campaign page of the project.

About This Project

Jennifer Reyes is a Kansas City based American inventor and mother of nine kids. She aims at creating educational and scientific smart toys for children to help them learn and play in a productive manner. She seeks support from parents and teachers worldwide for this project and she is welcoming everyone to become a part of her recently launched Kickstarter campaign.

Media Contact
Company Name: Science Smart Toys
Contact Person: Jennifer Reyes
Email: Send Email
Phone: 816-437-0395
Address:6044 E Truman Rd
City: Kansas City
State: Missouri
Country: United States

Jennifer Reyes
Science Smart Toys
+1 816-437-0395
email us here

Source: EIN Presswire

Chad Tackett Shows You How to Lose Weight and Gain Muscle

Chad Tackett Arizona

HAPPY VALLEY, OR, UNITED STATES, March 27, 2020 / — Losing weight is difficult for many people. You may tell yourself that you don't have the time or motivation to do so in order to complete your weight loss journey. For those who do end up losing the weight they want to get rid of, they end up sacrificing muscle mass in the process. This can leave some people frustrated with their body whenever they have climbed one mountain and they give up when they realize they have to climb another. Fortunately, Chad Tackett has created Committed 100 in order to help people achieve their fitness goals.

Losing weight and gaining muscle is entirely possible if you put the right resources together. Thankfully, Committed 100 is an online weight loss program that can help you achieve this. Committed 100 has dozens of training programs and meal plans that will help you lose weight and gain muscle. According to Committed 100's Chad Tackett, you are going to want to consider these factors whenever you are building muscle and losing weight:

– The amount of protein you are consuming
– Losing weight at a slower pace
– Incorporating strength training into your regiment
– Don't overdo it on the cardio
– Let your muscles relax

Consuming more protein whenever you are working out will give your body the fuel that it needs in order to build solid muscle. However, eating only protein and only doing strength training will cause you to gain an excessive amount of weight. This is why you want to balance out your workouts with some cardio. Chad Tackett recommends that you perform the 2/3 rule: 2/3 should be strength training and 1/3 should be cardio. This will allow you to get the strength training you need to get in and the cardio you need to lose that stubborn fat.

Committed 100's Chad Tackett wants you to know that working out regardless of what the activity is will burn calories. This is why it is important to put more of a focus on strength training. Don't eat too many carbs, stay away from junk food, and focus on your workout routine. You'll soon get those gains you've always wanted if you stick to Committed 100's workout plan.

More on Chad Tackett

In the past 25 years since creating Committed 100, the world’s first online weight loss program, Chad Tackett has helped people in over 100 countries, of various ages, sizes, and backgrounds, achieve their health and fitness goals. He endeavors to help people make healthy and sustainable lifestyle changes to live happier, healthier, and more fulfilling lives without giving up their favorite foods or suffering through boring workouts.

If you are ready to fundamentally change how you think about food for the long-term and “fix” your metabolism Visit to watch this free training by Chad Tackett at Committed 100.

Visit to learn more about the Committed 100 online weight loss program by Chad Tackett.

Caroline Hunter
Web Presence, LLC
email us here
+1 7862338220

Source: EIN Presswire

William Magagna Named Treasurer of LTEN Board of Directors

Life sciences training veteran William Magagna has been selected as treasurer of the LTEN Board of Directors.

ROANOKE, VA, UNITED STATES, March 27, 2020 / — Life sciences training veteran William Magagna has been selected as treasurer of the LTEN Board of Directors. The appointment, which begins immediately, runs through the end of 2021. Magagna succeeds Richard Sampson, who was named 2020-21 president of the LTEN Board of Directors.

Magagna, vice president, virtual education solutions, for Siemens Healthcare, has worked in virtual education and instructional design for more than 25 years, including the past 17 years with Siemens. Magagna has served on the LTEN Board of Directors since 2012.

“I was happy to step into the treasurer role after Richard’s selection as board president,” Magagna said. “After eight years on the board, I’ve seen how vital that role is to the management of our network and how much it affects members in ways they may not even realize. I look forward to working closely with the board, other officers on the board’s Executive Committee and LTEN staff to ensure we’re compliant, fiscally responsible and forward-thinking in our resource management.”

“Bill’s been a valued member of LTEN and of the board for a long time, and I know he’ll be a great asset to the leadership team,” said Dawn Brehm, LTEN executive director. “The treasurer role is a vital one, and Bill’s experience, reliability and attention to detail will serve LTEN well.”

The Life Sciences Trainers & Educators Network ( is the only global 501(c)(3) nonprofit organization specializing in meeting the needs of life sciences learning professionals. LTEN shares the knowledge of industry leaders, provides insight into new technologies, offers innovative solutions and communities of practice that grow careers and organizational capabilities. Founded in 1971, LTEN has grown to more than 2,100 individual members who work in pharmaceutical, biotech, medical device and diagnostic companies, and industry partners who support the life sciences training departments.

For more information contact Nannette Nolan, LTEN director of marketing communications, at

Nannette Nolan
Life Sciences Trainers & Educators Network
+1 424-266-0745
email us here
Visit us on social media:

Source: EIN Presswire